US Patent 8673304 Humanized anti-CD4 antibody with immunosuppressive properties
Patent 8673304 was granted and assigned to Biotest AG on March, 2014 by the United States Patent and Trademark Office.
All edits
Edits on 1 Dec, 2023
Golden AI
Edits made to:
Article (+197 characters)
Article
Patent abstract
A humanized antibody derived from mouse monoclonal anti-CD4 antibody B-F5 is able to activate CD25+CD4+ regulatory T cells and is useful for preparing immunosuppressive compositions.
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08673304 Humanized anti-CD4 antibody with immunosuppressive properties US Patent 8673304 Humanized anti-CD4 antibody with immunosuppressive properties
Infobox
Patent Number
0867330400
Patent Number
867330400
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
086733040
Date of Patent
March 18, 2014
0Patent Application Number
123925210
Date Filed
February 25, 2009
0Official Website
Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
086733040
Date of Patent
March 18, 2014
0Patent Application Number
123925210
Date Filed
February 25, 2009
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 22 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08673304 Humanized anti-CD4 antibody with immunosuppressive properties
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08673304
Date of patent
March 18, 2014
Patent application number
12392521
Date Filed
February 25, 2009
Patent primary examiner
Find more entities like US Patent 8673304 Humanized anti-CD4 antibody with immunosuppressive properties
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.